Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02987504 · ClinicalTrials.gov registry record · Phase 1
Study of Samalizumab in Patients With Advanced Cancer
A Phase 1 study, sponsored by Alexion Pharmaceuticals.
- Terminated
- Registry status
- Phase 1
- Development phase
- 10
- Enrollment target
NCT02987504 is a Phase 1 study that was terminated before completion, run by Alexion Pharmaceuticals. The registered enrollment target is 10 participants.
The verdict
NCT02987504, a Phase 1 study, was terminated before completion, sponsored by Alexion Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 10 participants
- Enrollment target
Study Summary
This is a multicenter, open-label, dose-escalation, Phase 1 study of intravenous (IV) samalizumab to determine its maximum tolerated dose (MTD), overall safety/tolerability, pharmacokinetic and pharmacodynamic parameters, and efficacy in participants with advanced cancer. The study was terminated for administrative reasons and not due to any safety concerns.
Interventions
- DRUG Samalizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2016-11-17 |
| Est. Completion | 2017-09-27 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02987504
The ClinicalTrials.gov registry entry for NCT02987504 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alexion Pharmaceuticals, which has 162 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Samalizumab is the first listed.
NCT02987504 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02987504 about?
NCT02987504 is a clinical study titled "Study of Samalizumab in Patients With Advanced Cancer". This is a multicenter, open-label, dose-escalation, Phase 1 study of intravenous (IV) samalizumab to determine its maximum tolerated dose (MTD), overall safety/tolerability, pharmacokinetic and pharmacodynamic parameters, and efficacy in participants with advanced cancer. The study was terminated fo...
What is the current status of trial NCT02987504?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2016-11-17. Estimated completion is 2017-09-27.
What interventions are being tested in trial NCT02987504?
The interventions under investigation include: Samalizumab (DRUG).
Who is sponsoring clinical trial NCT02987504?
This trial is sponsored by Alexion Pharmaceuticals, which has 162 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.